Imfinzi plus tarlatamab cut risk of death by 58% in first-line extensive-stage small cell lung cancer
FROM THE WIRE · FINANCE.YAHOO.COM
Novel combination demonstrated a median overall survival of nearly two years, the longest benefit ever reported in extensive stage disease in a Phase III trial Results reinforce IMFINZI as the backbone immunotherapy across stages of small cell lung cancer WILMINGTON, Del.…
Read at the source ↗MARKET IMPACTNEUTRAL✦ News Impact agent estimateTone: expected bullishA positive Phase III result strengthens AstraZeneca's oncology pipeline, with Imfinzi as the backbone immunotherapy.AI-generated summary
✦ IN BRIEF · AIAI-generated summary
- 01The DeLLphi-305 Phase III trial showed a statistically significant improvement in overall survival.
- 02The treatment reduced the risk of death by 58% in first-line extensive-stage small cell lung cancer.
- 03Median overall survival is nearly two years, according to the press release issued via Business Wire.
NEWS IMPACT AND MARKET REACTIONChange since the story · reference
Impact and summary are estimates by the News Impact AI agent, not financial advice.Open in Markets